Amarin Corp Plc (AMRN)

[umiak]

Thank you for your continued interest in Amarin Corp. Like you, everyone at Amarin is disappointed in the results of the Phase III trial of Miraxion to treat Huntington's disease. Management is currently evaluating the data to try to determine why these results did not match the earlier Phase III trial results in the subset patient population with CAG scores of 44 or less.

In addition to Miraxion, Amarin has a rich Central Nervous System (CNS) pipeline of products in development. The company plans on focusing on four key product programs:

1) Oral apomorphine for the "frozen" or "off" periods in advanced Parkinson's disease
2) Nasal lorazepam for the outpatient treatment of seizures in epileptic patients
3) Target transport of levodopa in Parkinson's disease via the company's proprietary combiniatorial lipid technology
4) AMR-109 for the enhancement of memory and cognition

Amarin management will be presenting the company and its refocused strategy at three upcoming investor conferences:

1) Rodman and Renshaw Global Healthcare Conference, May 15th
2) Banc of America Healthcare Conference, June 1st
3) FTN Midwest Financial Growth Conference, June 5th
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_A/threadview?m=tm&bn=998&tid=10...